| Application no. and date | 23215626.5 (espacenet) (Federated) (European Patent Register), 20190328 | | Patent/reg. no. and date | DK/EP 4327866, 20251210 | | Publication date | 20240228 | | Priority no. and date | US 201862650314 P, 20180330 | | EP pub. no. and date |
EP 4327866 20240228 | | Effective date | | | Applicant/owner | Eli Lilly and Company, Lilly Corporate Center
Indianapolis, IN 46285, US | | Applicant ref. no. | V499151DK00 | | Inventor | CANAVAN, James Benedict,
Indianapolis, 46206-6288, US,
FRIEDRICH, Stuart William,
Indianapolis, 46206-6288, US,
KRUEGER, Kathryn Ann,
Indianapolis, 46206-6288, US,
MILCH, Catherine,
Indianapolis, 46206-6288, US,
TUTTLE, Jay Lawrence,
Indianapolis, 46206-6288, US | | Representative | Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S | | Opponent | | | IPC Class | A61K 39/395 (2006.01) , A61P 1/04 (2006.01) , C07K 16/24 (2006.01) | | Title | MIRIKIZUMAB VED BEHANDLING AF ULCERØS KOLITIS | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
